The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model

Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)‐α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better‐tolerated drugs. Cilengitide (EMD 121974), a novel cyclic inhibitor of alpha‐V integrins, has both anti‐angio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2013-06, Vol.132 (11), p.2694-2704
Hauptverfasser:	ten Hagen, Timo L.M., Seynhaeve, Ann L.B., de Wiel‐Ambagtsheer, Gisela aan, de Bruijn, Ernst A., van Tiel, Sandra T., Ruegg, Curzio, Meyring, Michael, Grell, Matthias, Goodman, Simon L., Eggermont, Alexander M.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	alphaVbeta3 Animals Antineoplastic Agents, Alkylating - therapeutic use Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences Chemotherapy, Cancer, Regional Perfusion cilengitide Disease Models, Animal Drug Synergism EMD 121974 isolated limb perfusion Limb Salvage Male Medical sciences melphalan Melphalan - therapeutic use Rats Rats, Inbred BN Receptors, Vitronectin - antagonists & inhibitors sarcoma Sarcoma, Experimental - metabolism Sarcoma, Experimental - prevention & control Snake Venoms - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!